PharmaEssentia Corporation

BDL:261280558 Stock Report

Market Cap: US$6.1b

PharmaEssentia Valuation

Is 261280558 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 261280558 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 261280558 ($18.3) is trading below our estimate of fair value ($41.31)

Significantly Below Fair Value: 261280558 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 261280558?

Key metric: As 261280558 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 261280558. This is calculated by dividing 261280558's market cap by their current earnings.
What is 261280558's PE Ratio?
PE Ratio106.6x
EarningsNT$1.85b
Market CapNT$196.72b

Price to Earnings Ratio vs Peers

How does 261280558's PE Ratio compare to its peers?

The above table shows the PE ratio for 261280558 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average64.8x
ADMA ADMA Biologics
68.8x30.5%US$4.6b
AGIO Agios Pharmaceuticals
5.2x-56.4%US$3.4b
TLX Telix Pharmaceuticals
169.5x38.3%AU$8.3b
HALO Halozyme Therapeutics
15.7x21.1%US$6.1b
261280558 PharmaEssentia
106.6x92.0%US$196.7b

Price-To-Earnings vs Peers: 261280558 is expensive based on its Price-To-Earnings Ratio (106.6x) compared to the peer average (64.8x).


Price to Earnings Ratio vs Industry

How does 261280558's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
261280558 106.6xIndustry Avg. 28.1xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 261280558 is expensive based on its Price-To-Earnings Ratio (106.6x) compared to the European Biotechs industry average (28.1x).


Price to Earnings Ratio vs Fair Ratio

What is 261280558's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

261280558 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio106.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 261280558's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies